Asieris Pharmaceuticals released its semi-annual performance, with a net loss attributable to the parent company of 162 million yuan
I'm PortAI, I can summarize articles.
According to the Zhitong Finance APP, Asieris disclosed its semi-annual report for 2025, stating that the company achieved revenue of 130 million yuan during the reporting period, a year-on-year increase of 61.80%; the net profit attributable to the parent company was a loss of 162 million yuan; the net profit excluding non-recurring gains and losses was a loss of 177 million yuan; basic earnings per share were -0.29 yuan
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments